Table of Contents
Pharmaceuticals, Volume 13, Issue 10 (October 2020) – 64 articles
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story (view full-size image) This paper describes how novel anti-EGFR antibody-drug conjugates (ABT-414, ABBV-221, and ABBV-321) [...] Read more. This paper describes how novel anti-EGFR antibody-drug conjugates (ABT-414, ABBV-221, and ABBV-321) that selectively target a tumor-selective (mAb806) epitope were evaluated for the treatment of malignant mesothelioma. EGFR and mAb806 epitope expression in malignant mesothelioma cell lines was confirmed using in vitro assays. Biodistribution and imaging studies demonstrated specific targeting of malignant mesothelioma tumors using an 89Zr-labeled immunoconjugate-ch806. In vivo therapy studies were conducted in malignant mesothelioma xenograft and PDX tumor models. ABT-414, ABBV-221, and ABBV-322 resulted in significant growth inhibition in tumors with high EGFR and mAb806 epitope expression. In contrast, in an EGFR expressing PDX model that was negative for the mAb806 epitope, no growth inhibition was observed. View this paper.